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1302 The Journal of Thoracic and CardObjective: The use of left ventricular assist devices as a bridge to transplantation for
patients with chronic congestive heart failure is well accepted. However, few studies
have examined outcomes solely for these patients. This study details one center’s
left ventricular assist device experience with this population.
Methods: Two hundred one patients received HeartMate left ventricular assist devices
(Thoratec Corp, Pleasanton, Calif) from January 1, 1996, to April 30, 2004. Of these,
119 (59.2%) had chronic congestive heart failure (diagnosis6 months) as the primary
indication. Outcome parameters included early mortality after left ventricular assist
device placement (30 days), bridge-to-transplantation rate, and posttransplantation
survival. Variables examined included patient demographic data; preoperative pace-
maker, internal defibrillator, and balloon pump use; and preoperative laboratory values.
Results: Advanced age, female sex, and diabetes were independent predictors of early
death (P  .048, odds ratio 1.879 per 10 years of age, 95% confidence interval
1.005-3.515; P  .002, odds ratio 10.029, 95% confidence interval 2.256-44.583; P 
.040, odds ratio 3.974, 95% confidence interval 1.063-14.861). Advanced age, female
sex, and low preoperative albumin were independent predictors of poor bridge-to-
transplantation rate (P  .029, odds ratio 0.135 per 10 years of age, 95% confidence
interval 0.022-0.819; P .002, odds ratio 0.013, 95% confidence interval 0.001-0.197;
P  .023, odds ratio 19.178 per 1 g/dL albumin, 95% confidence interval 1.504-
244.598). There were no independent predictors of poor posttransplantation survival and
prolonged intensive care unit stay. Overall bridge-to-transplantation rate was 81.5%. The 1-,
3-, 5-, and 7-year posttransplantation survivals were 88.4%, 84.5%, 78.4%, and 76.0%.
Conclusion: Among patients with chronic congestive heart failure, advanced age,
female sex, diabetes, and low preoperative albumin predict poor clinical course. Careful
risk stratification and comprehensive evaluation by care providers should be performed
for candidates who are female, are elderly, and have diabetes, and preoperative nutri-
tional optimization should be encouraged to enhance patient outcomes.
The use of left ventricular assist devices (LVADs) as a support option forpatients with severe, end-stage heart failure is well accepted. LVADs havefound application across a range of heart failure syndromes, both acute and
chronic. In the acute setting, they have been successfully used for such entities as
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Ppostcardiotomy shock,1,2 acute myocardial infarction and
cardiogenic shock,3,4 acute myocarditis,5-7 and peripartum
cardiomyopathy.8 Because of the acute nature of these ill-
nesses, however, morbidity and mortality within this popu-
lation remain exceedingly high.
Conversely, chronic congestive heart failure (CHF) fol-
lows a different clinical course. The nature of the disease is
progressively and consistently deteriorating. Although in
most patients with chronic CHF, LVADs are in fact in-
tended to bridge to transplantation, the Randomized Evalu-
ation of Mechanical Assistance for the Treatment of Con-
gestive Heart Failure (REMATCH) trial recognized
permanent, destination LVAD therapy as a valid alternate
clinical end point.9 The proven benefits of LVAD therapy
relative to optimal medical management make it likely that
more and more elderly patients with heart failure will be
referred for LVAD implantation in the future. As such,
age-related health factors and comorbidities need to be
carefully considered, and patient selection will play an
increasingly critical role in the determination of clinical
outcomes.
The purpose of this study was to characterize our cen-
ter’s clinical LVAD experience solely with the population
being treated for chronic CHF. By identifying preoperative
factors that predict postoperative end points, we hoped to
optimize preoperative status and tailor selection criteria to
enhance patient outcomes.
Patients and Methods
This study protocol was approved by the institutional review board
of Columbia University College of Physicians and Surgeons, New
York, NY. Data were retrospectively analyzed after databases
were stripped of all patient identifiers, and a unique code number
was used for each study subject.
Chronic CHF was defined as heart failure diagnosed more than
6 months before LVAD insertion. All patients evaluated for LVAD
insertion had New York Heart Association class IV symptoms.
Patients with diagnoses for less than 6 months and those who
underwent LVAD insertion under acute circumstances (eg, post-
cardiotomy shock, acute myocardial infarction and cardiogenic
shock, acute myocarditis, and peripartum cardiomyopathy) were
Abbreviations and Acronyms
BSA  body surface area
CHF  congestive heart failure
ICU  intensive care unit
LOS  length of stay
LVAD  left ventricular assist device
REMATCH  Randomized Evaluation of Mechanical
Assistance for the Treatment of
Congestive Heart Failureexcluded. Those requiring LVAD insertion for acute heart failure
The Journal of Thoracicsuperimposed on underlying chronic heart failure were similarly
excluded.
From January 1996 to April 2004, a total of 201 patients
underwent HeartMate LVAD (Thoratec Corp, Pleasanton, Calif)
insertion at our institution. Of these, 119 (59.2%) had chronic CHF
as the primary indication. All patients were under evaluation for
cardiac transplantation at the time of LVAD insertion. Thus no
patients designated to receive LVADs for permanent, destination
therapy were included.
The clinical characteristics of the patients receiving LVADs for
chronic CHF are outlined in Table 1. The vast majority of patients
(87.4%) were male, and the most common etiology for heart
failure was idiopathic (dilated) cardiomyopathy.
Outcome parameters included duration of LVAD support, total
hospital length of stay (LOS), intensive care unit (ICU) LOS,
post-LVAD early mortality (30 days), bridge-to-transplantation
rate, and posttransplantation survival. Preoperative variables in-
cluded patient demographic data; pacemaker, automatic implant-
able cardiac defibrillator, and intra-aortic balloon pump use;
LVAD risk factor score; and serum laboratory values. The LVAD
risk factor score used derives from a screening scale that identifies
TABLE 1. Clinical characteristics of LVAD recipients with
chronic CHF
Characteristic Value
Age (y, mean  SD) 52  12
Sex (No.)
Male 104 (87.4%)
Female 15 (12.6%)
CHF etiology (No.)
Coronary artery disease 49 (41.1%)
Idiopathic cardiomyopathy 56 (47.1%)
Other 14 (11.8%)
Body mass index (kg/m2, mean  SD) 26.7  5.5
Diabetes mellitus (No.) 29 (24.4%)
Hypertension (No.) 32 (26.9%)
Preoperative arrhythmia (No.) 61 (51.3%)
Preoperative pacemaker (No.) 22 (18.5%)
Preoperative automatic implantable cardiac
defibrillator (No.)
31 (26.1%)
Smoking history (No.) 39 (32.8%)
Alcohol history (No.) 17 (14.3%)
Preoperative intra-aortic balloon pump (No.) 17 (14.3%)
LVAD risk factor score* (mean  SD) 2.7 2.7
Blood urea nitrogen (mg/dL, mean  SD) 45.6 25.3
Creatinine (mg/dL, mean  SD) 1.9 0.8
Total protein (g/dL, mean  SD) 6.7  1.0
Albumin (g/dL, mean  SD) 3.7 0.5
Total bilirubin (mg/dL, mean  SD) 2.4 2.7
Direct bilirubin (mg/dL, mean  SD) 0.9 1.4
Aspartate aminotransferase (U/L, mean  SD) 85.2 174.3
Alanine aminotransferase (U/L, mean  SD) 97.3 248.3
Alkaline phosphatase (U/L, mean  SD) 107.9 55.3
CHF, Congestive heart failure; LVAD, left ventricular assist device; SD,
standard deviation. *Out of 10 possible points.preoperative risk factors shown to adversely affect survival after
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CSPLVAD insertion.10,11 These include ventilation dependence, post-
cardiotomy shock, previous LVAD, prothrombin time longer than
16 seconds, and central venous pressure greater than 16 mm Hg.
LVAD implantation scores are calculated from these five clinical
variables, and there is typically an inverse relationship between
score and clinical stability. Preoperative serum laboratory values
included blood urea nitrogen, creatinine, total protein, albumin,
total bilirubin, direct bilirubin, aspartate aminotransferase, alanine
aminotransferase, and alkaline phosphatase.
Prediction analyses were run for four clinical outcomes: post-
LVAD early mortality (30 days), prolonged ICU LOS (14
days), bridge-to-transplantation rate, and posttransplantation sur-
vival. Data were examined univariately with the Student t test for
continuous variables and with the 2 test for discrete data. Kaplan-
Meier analysis was used to calculate survival. Actuarial survivals
at 1, 3, 5, and 7 years after transplantation were calculated by
constructing life tables. Variables with a P value less than .25 were
entered into a logistic regression analysis for multivariable analy-
sis. This multiple regression analysis examined variables with
dichotomous outcomes (such as early mortality) and their potential
associated risk factors by means of a linearized function of a set of
Figure 1. Posttransplantation survival.
TABLE 2. Multivariate analysis: Independent predictors of
Risk factor Variable estimate SE
Age 0.631 0.319
Female sex 2.305 0.761
Diabetes 1.380 0.673
SE, Standard error; OR, odds ratio; CI, confidence interval. Hosmer-Lemes
age.
1304 The Journal of Thoracic and Cardiovascular Surgery ● Novcovariates. Risk factors allowed into the final model with a result-
ant P value less than .05 were interpreted as independently asso-
ciated with the event, above other potential risk factors in the
equation. All data were analyzed with SPSS version 11.5 software
(SPSS, Inc, Chicago, Ill).
Results
Duration of LVAD Support
The mean duration of LVAD support for all patients was 71
 72 days (median 48 days, range 0-448 days). The mean
durations of LVAD support until transplantation or death
were 81  75 days (median 57.5 days, range 4-448 days)
and 28  33 days (median 23 days, range 0-139 days),
respectively.
Hospital and ICU LOSs
Mean total hospital LOS was 33  24 days (median 27.5
days, range 0-139 days). Mean ICU LOS was 15  18 days
(median 10 days, range 0-139 days).
Clinical Outcomes
Twenty of 119 patients (16.8%) died after LVAD implan-
tation. Thirteen (10.9%) of these deaths occurred within 30
days, and 7 (5.9%) occurred after 30 days. Excluding the 11
patients who were still receiving LVAD support at the end
of the study, 88 (81.5%) of 108 patients were successfully
bridged to transplantation. All patients in this study were
candidates for cardiac transplantation before LVAD inser-
tion, and none underwent LVAD explantation for myocar-
dial recovery. Posttransplantation actuarial survivals at 1, 3,
5, and 7 years were 88.4%, 84.5%, 78.4%, and 76.0%,
respectively (Figure 1).
Predictors of Clinical Outcomes
Independent predictors of early death (30 days) are shown
in Table 2. These included advanced age, female sex, and
diabetes mellitus. Advanced age predisposed toward early
death by 1.9 times for every additional 10 years of age. The
presence of diabetes mellitus increased early mortality
nearly 4 times, yet the greatest risk factor was female sex
(women were 10 times more likely to die than their male
counterparts). The clinical characteristics of all female pa-
tients with LVADs are shown in Table 3.
y death
P value OR 95% CI
.048 1.879* 1.005-3.515
.002 10.029 2.256-44.583
.040 3.974 1.063-14.861
oodness-of-fit test P value .722. *Odds ratio for every 10-year increase inearl
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onary
Dang et al Cardiopulmonary Support and Physiology
CS
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shown in Table 4. Advanced age, female sex, and low
preoperative serum albumin predicted a poor bridge-to-
transplantation rate. For every 10-year increase in age, the
likelihood of bridging to transplantation was reduced by a
factor of 0.135 (odds ratio). For every 1-g/dL increase in
preoperative serum albumin level, there was a 19.2 times
greater likelihood of bridging to transplantation. The odds
ratio for female patients successfully bridging to transplan-
tation was a mere 0.013.
There were no independent predictors of prolonged ICU
LOS or posttransplantation survival.
Discussion
The number of patients who underwent LVAD insertion on
an emergency basis at our institution has gone down during
recent years. Previously, we reported that 73 of 115 patients
(63%) had required emergency LVAD placement during a
6-year period.12 The remaining 37% received LVADs in a
nonurgent setting. In this study, the reverse was true, with
119 of 201 patients (59%) in an 8-year period undergoing
nonurgent LVAD placement and the remaining 41% of
patients undergoing emergency placement. The reasons for
this shift in the urgency setting of LVAD implantation may
have to do with a greater number of referrals for LVAD
placement of patients with chronic CHF relative to patients
with acute heart failure. As LVADs continue to gain wider
recognition as a definitive mode of therapy for chronic CHF,
we anticipate this shift toward implanting them on a non-
urgent basis to become even more pronounced.
Overall, the clinical outcomes of this patient cohort com-
TABLE 3. Clinical characteristics of female LVAD recipien
Patient Age (y) Diagnosis Previous cardiot
1 65 ICM No
2 63 ICM No
3 59 CAD Yes
4 32 ICM No
5 61 Viral CM, CAD Yes
6 60 CAD No
7 57 ICM No
8 55 CAD No
9 27 Postpartum CM No
10 58 CAD Yes
11 48 Amyloidosis No
12 62 ICM No
13 57 Doxorubicin-induced CM No
14 56 Dilated CM No
15 57 Rheumatic valvular CM Yes
ICM, Idiopathic cardiomyopathy;MSOF, multisystem organ failure; CAD, corpared favorably with those of other large LVAD experi-
The Journal of Thoracicences. The bridge-to-transplantation success rate of 81.5%
was greater than the 60% to 73% rate reported in other
studies,13-15 although it is true that those studies also in-
cluded patients receiving LVADs for acute heart failure,
which carries a higher mortality in general. Among those
who were successfully bridged to transplantation, posttrans-
plantation survivals were equivalent to those reported in
other LVAD studies13-15 and to those attained by transplant
recipients bridged by medical therapy alone.16
Advanced age was determined to be an independent
predictor of both early death and poor bridge to transplan-
tation. The mean age in this study was 52  12 years
(median 55 years), although there were 32 patients older
than 60 years, and the oldest patient included was 69 years
old. The negative influence of increasing age has also been
reported in other studies. Deng and colleauges17 found that
age greater than 65 years was a significant risk factor for
death in a study of 464 patients with end-stage heart failure
who received the Novacor LVAD. Frazier and associates18
noted age to be a risk factor for poor survival to transplan-
tation in a multicenter analysis of 280 patients with the
HeartMate LVAD. More recently, Jurmann and col-
leagues19 described a 37% 30-day post-LVAD mortality
among patients older than 60 years and with contraindica-
tions to cardiac transplantation. Although there are no ab-
solute exclusion criteria for LVAD implantation by age
alone among bridge-to-transplantation candidates, many
surgeons accept 65 years as a reasonable cutoff. This thresh-
old relates, at least in part, to the fact that age greater than
65 years is a contraindication to cardiac transplantation at
most institutions. This principle was upheld in the RE-
Support time (d) Status* Cause of death
3 Died MSOF
2 Died Right ventricular failure
124 Transplant NA
58 Transplant NA
12 Died Hemorrhage from aorta–left
atrium fistula, dissection
47 Died Sepsis
105 Transplant NA
30 Transplant NA
101 Transplant NA
32 Transplant NA
25 Died Large cerebrovascular
accident
16 Died MSOF
77 Died Sepsis
21 Died Biventricular failure
31 Ongoing NA
artery disease; NA, not applicable; CM, cardiomyopathy. *At end of study.ts
omyMATCH trial; patients who were designated to receive
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study specifically because they were not candidates for
transplantation. In that study, the mean age was 66  9
years, and advanced age was the most common reason for
ineligibility for transplantation. Although patients aged 60
to 69 years who received LVADs had a 1-year survival
inferior to those younger than 60 years (47% vs 74%), their
survival was still superior to their 60- to 69-year-old coun-
terparts who received medical therapy (15%). With similar
logic, LVAD placement in 60- to 69-year-old bridge-to-
transplantation candidates may not yield the same survival
as placement into patients younger than 60 years, but sur-
vival may still be sufficient to justify the effort. The use of
LVADs in this regard may therefore lead to selection of
only the most well-suited patients for transplantation, a
process that ultimately might dictate the more judicious
allocation of allografts.
Female sex was also determined to be an independent
predictor of both early death and poor bridge to transplan-
tation. Although there were only 15 female LVAD recipi-
ents, 8 (53.3%) of them died, and only 6 of 14 (42.9%) were
successfully bridged to transplantation (1 patient was still
receiving LVAD support at the end of the study). Much
attention has previously been directed toward female sex as
an independent risk factor for death after coronary artery
bypass grafting,20,21 although recent opinion holds that
prevalence of comorbid risk factors in women, not gender
per se, is what truly affects these midterm and long-term
survivals.22 Higher mortality has also been reported among
female LVAD recipients,23 and the purported reasons have
again been considered to be related to gender differences in
disease epidemiology and timeliness of heart failure man-
agement. Smaller body size has been associated with in-
creased operative mortality.24 Although the female patients
in this study did, in fact, have lower body surface areas
(BSAs) than their male counterparts (1.8  0.2 m2 vs 2.0 
0.2 m2, P  .01), only 1 female patient actually had a BSA
less than 1.5 m2, the lower limit indicated for HeartMate
implantable LVADs. Still, lower BSA in general may con-
tribute to adverse outcomes as a result of diminished capac-
ity to accommodate the device, more pronounced posterior
displacement of the stomach, and impaired wound healing.
Other important factors that could contribute to higher mor-
TABLE 4. Multivariate analysis: Independent predictors of
Risk factor Variable estimate SE
Age 2.006 0.921
Female sex 4.341 1.387
Albumin 2.954 1.299
SE, Standard error; OR, odds ratio; CI, confidence interval. Hosmer-Lemesh
in age. †Odds ratio for every 1-g/dL increase in serum albumin level.tality among female recipients include relatively longer
1306 The Journal of Thoracic and Cardiovascular Surgery ● Novwaiting times to transplantation because of more stringent
donor-recipient size-matching criteria and a greater propen-
sity toward psychosocial disturbance after the operation.25
Further investigation into these issues, among other gender-
based anatomic and physiologic differences, is warranted to
facilitate understanding and mediation of these disparate
clinical outcomes.
Diabetes mellitus was present in 29 of 119 patients
(24.4%) and conferred a near 4-fold increased risk for early
death. The concern with diabetes in patients receiving
LVADs rests on two grounds: its frequent comorbidity with
damage of other end organs, particularly the kidneys, and
the potential for accelerated allograft vasculopathy in pa-
tients who are ultimately bridged to transplantation. Type 1
diabetes mellitus with end-organ damage is in fact a con-
traindication to transplantation, and this policy stems from
concern regarding increased infection during immunosup-
pression therapy, increased metabolic derangements, and
the development of transplant coronary artery disease.26
The REMATCH trial excluded neither elderly patients nor
those with diabetes from receiving LVADs for destination
therapy. Improved long-term survival data for these patients
with diabetes would allow us to be more optimistic about
outcomes in the bridge-to-transplantation population, but
until these improvements are realized, only the most care-
fully selected patients with diabetes, those with minimal
comorbidities, should be considered for LVAD implanta-
tion, and there must be vigilant management of diabetes
during the postoperative period.
Preoperative serum albumin was used as a surrogate for
nutritional status and was found to be an independent pre-
dictor of bridge to transplantation. This association was
marked, with a nearly 20-fold increase in bridge rate for
every 1-g/dL increase in serum albumin. The significance of
nutritional status in the patient with LVAD implantation is
often overlooked in the context of more acute management
issues but has gained recognition as a target area for im-
provement. Much of this focus comes from observations
that poor nutritional status is associated with increased
morbidity and mortality among surgical patients in general,
but particularly the elderly population. In this regard,
LVAD implantation qualifies as among the most serious of
ge to transplantation
P value OR 95% CI
.029 0.135* 0.022-0.819
.002 0.013 0.001-0.197
.023 19.178† 1.504-244.598
oodness-of-fit test P value  .604. *Odds ratio for every 10-year increasebrid
ow gphysiologic insults, because it represents highly invasive
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tients in a chronic inflammatory state.
Preoperative malnutrition predisposes LVAD recipients
toward a range of infectious complications and impaired
wound healing. The true extent to which infectious compli-
cations develop as a direct result of preoperative malnutri-
tion is not known, but there seems to be a clear positive
indication, both from a clinical and an economic standpoint,
for reversing the long-term effects of malnutrition to restore
immunologic function.27
The importance of nutritional assessment has been
looked at previously28 and focuses on accurate evaluation of
a patient’s preoperative nutritional status. In addition to
serum albumin levels, serial assessments should also be
made of prealbumin, transferrin, retinol-binding protein,
total and absolute lymphocyte counts, and C-reactive pro-
tein. The goal for patients scheduled for LVAD implanta-
tion on a nonurgent basis would be to provide nutritional
supplementation according to individual caloric and sub-
strate needs. Once patients have optimal nutrition, they can
then enter their operation at less of a disadvantage; however,
they should continue with nutritional supplementation (pref-
erably enterally delivered) well into the intermediate post-
operative period.
In contrast to studies by other large LVAD centers,29,30
preoperative variables not identified as risk factors for early
mortality or lower bridge-to-transplantation rate included
etiology of heart failure, lower BSA, elevated blood urea
nitrogen, creatinine and total bilirubin levels, reoperation
status, and recent LVAD use. However, it is important to
note that these other studies included patients with acute
heart failure in addition to those with chronic CHF, which
affects clinical characteristics considerably. These differ-
ences in risk factors are reflected in the distribution of heart
failure etiology alone in the study populations; whereas
other centers have reported that upward of 69% of LVAD
recipients have ischemic cardiomyopathy, we report a
greater number of patients whose cardiomyopathy is idio-
pathic (47%) than ischemic (41%) in nature. This difference
in disease etiology, among multiple other factors, may have
important implications regarding the likelihood and nature
of previous cardiac surgery procedures, as well as any
preoperative embarrassment of end-organ function. When
looking at both acute and chronic heart failure patients, our
experience is comparable to those of other centers with
similarly identified preoperative risk factors for
mortality.10,11
Study Limitations
This was a retrospective analysis that selected patients who
had received LVADs and worked backward to identify the
exact indications for insertion. Data collection was not
complete in all fields and cannot be as accurate as that
The Journal of Thoracicobtained in a prospective clinical trial. Because the number
of preoperative variables was limited, the study potentially
misses stronger independent predictors of mortality, or even
important covariates that might otherwise have negated the
predictors identified in this study.
We defined chronic CHF as heart failure that had been
diagnosed for longer than 6 months before LVAD insertion.
Although this time frame is sufficient in most cases to
validate a diagnosis of chronic CHF, particularly when
coupled with a thorough cardiac transplantation evaluation,
it excludes patients with diagnoses of heart failure for less
than 6 months. A similar selection bias is introduced by
excluding all patients who had acute CHF superimposed on
chronic CHF necessitating LVAD insertion.
Our inclusion of preoperative diabetic status failed to
discern between type 1 and type 2 subtypes of diabetes
mellitus. This is an important distinction, because these
groups often have different pathologic mechanisms, disease
manifestations, comorbidities, and approaches to manage-
ment. Preoperative serum albumin was selected as a general
surrogate for nutritional status, whereas in fact there are a
number of other serum markers and diagnostic tests that
collectively provide a more accurate representation. These
include, for example, serum prealbumin, transferrin, retinol-
binding protein, total and absolute lymphocyte counts, skin-
fold thickness measurements, indirect calorimetry, and du-
al-energy x-ray absorptiometric scans. Again, however, the
retrospective nature of this study precluded collection of
such comprehensive data, and we were therefore con-
strained to use cruder parameters.
Conclusions
Among patients with chronic CHF who undergo LVAD
insertion as a bridge to transplantation, advanced age, fe-
male sex, diabetes, and low preoperative serum albumin
predict poor clinical course. Careful risk stratification and
comprehensive evaluation by care providers should be per-
formed for elderly candidates and those with diabetes. Fur-
ther investigation into gender-based heart failure manage-
ment issues, as well as anatomic and physiologic
differences, is warranted to gain insight to the reasons
behind worse outcomes in female patients. Preoperative
nutritional optimization will play an increasingly important
role in curbing device-related infections and promoting
proper wound healing.
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Discussion
Dr Robert C. Robbins (Stanford, Calif). I am struggling a bit to
understand what is really new here. Now you are going to tell me,
you looked at your overall experience and are taking just about the
chronic cases. So help me understand a little better about what
these patients actually were really like. I am assuming they were
all in the hospital, in the ICU, with intravenous lines.
Dr Dang. All of them had New York Heart Association class
IV symptoms. They may not necessarily all have been inpatients,
but for the most part we tried to select patients who received
implants less on an emergency basis and more on a nonurgent
basis.
Dr Robbins. I can understand that part, but what you just said
would lead me to believe there were a few patients who came from
home to have the LVAD placed, sort of semielectively? This was
probably not the case. So my question concerns the definition of
having heart failure for longer than 6 months; what does that really
mean? Does that mean they had been seen in your clinic, had been
treated by a physician?
One of the things you could do is say, as you did in your article
and I was trying to get you to say here, is that they were receiving
-blockers and all those kinds of things. I would just like to better
define the population.
Dr Dang. Thank you for the clarification.
Dr Georg Lutter (Kiel, Germany). I totally agree with Dr
Robbins. I have two questions: First, as listeners, we would like to
know about the etiology of the chronic CHF. Second, did you also
see patients who were bridged to recovery? Did they all undergo
heart transplantation, or did you also see patients in whom a
combination of an assist device and a coronary artery bypass
grafting were performed, or did you do subsequent procedures in
these patients to let them recover?
Dr Dang. Thank you for the question, Dr Lutter. As far as
bridge to recovery, such patients were excluded. There were ac-
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initially, there were probably only 4 who were bridged success-
fully to recovery. All patients intended to bridge to transplantation
were included, and none underwent concomitant procedures with
LVAD insertion.
Dr Lutter. What was the etiology of the chronic CHF?
Dr Dang. Most of these cases were ischemic and idiopathic in
nature.
Dr John G. Byrne (Nashville, Tenn). Have you considered
looking at trying to develop a scoring system to weigh these
various risk factors? You had an odds ratio of 20 in one case, an
odds ratio of 2 or 3 in other cases. Say you gave 3 points for an
odds ratio of 20, and so forth. So if a patient has advanced age,
female sex, diabetes, and malnutrition, you probably should not
place an LVAD, but if a patient has one or maybe two of these
factors, you would think about it. That may mean combining your
database with other, larger databases.
Dr Dang. Thank you, Dr Byrne. That is an excellent point. An
LVAD scoring system does exist for all potential LVAD recipi-
ents; this was actually developed at our center. But the issue with
that LVAD scoring system is that it also includes patients with
acute heart failure, many of whom cannot be controlled for pre-
operatively.
I think it makes a lot of sense to develop a scoring systemThe Journal of Thoracicreceiving an implant on a nonurgent basis, could have their
status optimized preoperatively in such areas as nutrition and
diabetic management. We are in the process of trying to put
together a scoring system that includes some of these risk
factors.
Dr Mark J. Krasna (Baltimore, Md). You pointed out the
importance of nutrition. I am wondering how you have changed
your clinical evaluation to take that into account. Obviously, you
measured albumin. There are a lot of other more sensitive ways to
do that. What are you currently doing?
Dr Dang. We are presently running a clinical trial at our center
that seeks to determine whether there is a role for immune-
enhanced nutritional supplementation in the perioperative period
for the purpose of lowering infection rates.
With respect to following nutritional status, we get preoperative
laboratory values and then test again at various postoperative
intervals, from 1 to 16 weeks. Different nutritional parameters are
assessed, including albumin and prealbumin, as are inflammatory
markers such as C-reactive protein. We also look at other protein
markers, such as retinol-binding protein and transferrin. Finally,
we obtain dual-energy x-ray absorptiometric scans both before the
operation and 16 weeks after it. Dual-energy x-ray absorptiometric
scans have previously been used to assess bone density, but they
are also useful in assessing peripheral lean body mass, particularlyCS
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